The AJMC® Cholangiocarcinoma compendium is a comprehensive resource for clinical news and expert insights about this rare cancer of the bile duct.
December 19th 2022
Overall survival for patients with combined hepatocellular-cholangiocarcinoma is poor, but those who received adjuvant transarterial chemoembolization (TACE) after surgery had a prolonged recurrence-free survival (RFS).
Study Supports Comprehensive Genomic Profiling for Patients With Biliary Tract Cancer
September 24th 2022A small study suggests that comprehensive genomic profiling can help with clinical decision-making and predicting clinical outcomes in advanced biliary tract cancer, but further research is needed.
Read More
Case Report Describes Youngest Recorded Patient With Intrahepatic Sarcomatoid Cholangiocarcinoma
September 24th 2022The rare condition can easily be confused with hepatocellular carcinoma, but immunohistochemical studies can help accurately diagnose intrahepatic sarcomatoid cholangiocarcinoma.
Read More
Durvalumab With Chemo Wins FDA Approval in Treatment of Biliary Tract Cancers
September 6th 2022An estimated 1 in 4 patients treated with durvalumab and chemotherapy (gemcitabine plus cisplatin) was alive at 2 years compared with 1 in 10 treated with chemotherapy alone, with these results contributing to the FDA's approval of the first immunotherapy to treat these cancers.
Read More
Researchers From Spain Find Option to Detect FGFR2 Fusion in Plasma
July 2nd 2022Vall d'Hebron Institute of Oncology, a research group from Barcelona, Spain, has presented a method to detect FGFR2 fusion in plasma, which they say is “especially relevant” since the arrival of pemigatinib to treat patients with recurrent intrahepatic cholangiocarcinoma (iCCA).
Read More